Products
Companies
News
About
About
Add your product
Contact
Newsletter
×
Subscribe to our monthly newsletter
Subscribe
Products
ProFound AI for Digital Breast Tomosynthesis
ProFound AI for Digital Breast Tomosynthesis
iCAD
The concurrent-read, cancer detection and workflow solution from iCAD analyzes each tomosynthesis image, detecting both malignant soft tissue densities and calcifications.
Built on deep-learning and artificial intelligence technology, ProFound AI for breast tomosynthesis assists radiologists in addressing the challenges of reading tomosynthesis.
Formerly branded as PowerLook Tomo Detection 2.0
Information source:
Vendor
Last updated:
June 21, 2022
General Information
Technical Specifications
Regulatory
Market
Evidence
General Information
General
Product name
ProFound AI for Digital Breast Tomosynthesis
Company
iCAD
Subspeciality
Breast
Modality
Mammography
Disease targeted
Breast cancer
Key-features
Malignancy detection, calcification detection, certainty scoring, case scoring
Suggested use
Before: adapting worklist order
During: perception aid (prompting all abnormalities/results/heatmaps)
Technical Specifications
Data characteristics
Population
Asymptomatic screening population
Input
3D Digital Breast Tomosynthesis
Input format
DICOM
Output
Leasion score with segmentation overlay, case score, choice in operating point (high/med/low)
Output format
DICOM Structured Report, GSPS, Secondary Capture
Technology
Integration
Integration in standard reading environment (PACS), Stand-alone third party application, Provides case score in worklist when applicable
Deployment
Locally on dedicated hardware
Trigger for analysis
Automatically, right after the image acquisition
Processing time
1 - 10 minutes
Regulatory
Certification
CE
Certified, Class IIa
, MDD
FDA
510(k) cleared , Class II
Intended Use Statements
Intended use (according to CE)
ProFound AI® Software is a computer-assisted detection and diagnosis (CAD) software device intended to be used concurrently by interpreting physicians while reading digital breast tomosynthesis (DBT) exams from compatible DBT systems. The system detects soft tissue densities (masses, architectural distortions and asymmetries) and calcifications in the 3D DBT slices. The detections and Certainty of Finding and Case Scores assist interpreting physicians in identifying soft tissue densities and calcifications that may be confirmed or dismissed by the interpreting physician.
Market
Market presence
On market since
03-2018
Distribution channels
Tempus Pixel, RMS Medical Devices, Sectra Amplifier Store, GE and local Distributors
Countries present (clinical, non-research use)
25
Paying clinical customers (institutes)
1300
Research/test users (institutes)
30+
Pricing
Pricing model
Based on
Evidence
Evidence
Peer reviewed papers on performance
Patient Characteristics Impact Performance of AI Algorithm in Interpreting Negative Screening Digital Breast Tomosynthesis Studies
(read)
Using artificial intelligence in the diagnosis of breast cancer: First results after implementation in a radiology department of a breast clinic
(read)
Retrospective comparison between single reading plus an artificial intelligence algorithm and two-view digital tomosynthesis with double reading in breast screening
(read)
Non-peer reviewed papers on performance
Artificial Intelligence for Digital Breast Tomosynthesis - Reader Study Results
(read)
Other relevant papers